The effects of HCV infection and management on health-related quality of life (Q36746575)

16 August 2017

1 reference

title

The effects of HCV infection and management on health-related quality of life (English)

1 reference

16 August 2017

1 reference

Zobair Younossi

1 reference

16 August 2017

Jillian Kallman

series ordinal

1 reference

16 August 2017

John Kincaid

series ordinal

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

806-816

1 reference

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

16 August 2017

cites work

1 reference

A SELF-RATING DEPRESSION SCALE

21 January 2018

1 reference

Mental and physical symptoms associated with lower social support for patients with hepatitis C.

21 January 2018

1 reference

Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals

21 January 2018

1 reference

The impact of liver disease on health-related quality of life: a review of the literature

21 January 2018

1 reference

7 January 2021

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group

1 reference

7 January 2021

Depression, anemia and health-related quality of life in chronic hepatitis C.

1 reference

7 January 2021

1 reference

7 January 2021

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

7 January 2021

Improvement in quality of life measures in patients with refractory hepatitis C, responding to re-treatment with Pegylated interferon alpha -2b and ribavirin

1 reference

7 January 2021

Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease

1 reference

7 January 2021

Utility of a depression score to predict candidacy for hepatitis C virus therapy in veterans: a prospective longitudinal study

1 reference

7 January 2021

1 reference

7 January 2021

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

1 reference

7 January 2021

Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment

1 reference

7 January 2021

A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C

1 reference

7 January 2021

Quality of life and cognitive function in hepatitis C at different stages of liver disease

1 reference

7 January 2021

1 reference

7 January 2021

1 reference

7 January 2021

1 reference

7 January 2021

Australian women's experiences of living with hepatitis C virus: results from a cross-sectional survey

1 reference

7 January 2021

Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life

1 reference

7 January 2021

Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C.

1 reference

7 January 2021

Subclinical impairment of brain function in chronic hepatitis C infection

1 reference

7 January 2021

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

1 reference

7 January 2021

Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis

1 reference

7 January 2021

Impaired health-related quality of life in Romanian patients with chronic viral hepatitis before antiviral therapy

1 reference

7 January 2021

Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment

1 reference

7 January 2021

Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection

1 reference

7 January 2021

Fatigue in patients with chronic hepatitis C.

1 reference

7 January 2021

The impact of diagnosis of hepatitis C virus on quality of life.

1 reference

7 January 2021

Determinants of quality of life in chronic liver patients

1 reference

7 January 2021

Biopsychosocial predictors of health-related quality of life in patients with chronic hepatitis C.

1 reference

7 January 2021

Determinants of health-related quality of life in patients with chronic liver diseases

1 reference

7 January 2021

Biopsychosocial predictors of fatigue in chronic hepatitis C

1 reference

7 January 2021

Depression and anxiety in patients with hepatitis C: prevalence, detection rates and risk factors

1 reference

7 January 2021

Central nervous system changes in hepatitis C virus infection

1 reference

7 January 2021

Emerging evidence of hepatitis C virus neuroinvasion

1 reference

7 January 2021

Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial

1 reference

7 January 2021

Clinical relevance of cognitive scores in hepatitis C patients with advanced fibrosis

1 reference

7 January 2021

Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease

1 reference

7 January 2021

Hepatitis C: The clinical spectrum of disease

1 reference

7 January 2021

Depression, fatigue, and functional disability in patients with chronic hepatitis C.

1 reference

7 January 2021

"They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C.

1 reference

7 January 2021

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

1 reference

7 January 2021

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

1 reference

7 January 2021

A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan

1 reference

7 January 2021

Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C.

1 reference

7 January 2021

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

7 January 2021

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

1 reference

7 January 2021

Clinical toxicity of interferons in cancer patients: a review

1 reference

7 January 2021

Use of growth factors with antiviral therapy for chronic hepatitis C.

1 reference

7 January 2021

Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response.

1 reference

7 January 2021

Fatigue complicating chronic liver disease

1 reference

7 January 2021

Does methylphenidate reduce the symptoms of chronic fatigue syndrome?

1 reference

7 January 2021

Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: a preliminary report

1 reference

7 January 2021

Patient-controlled methylphenidate for cancer fatigue: a double-blind, randomized, placebo-controlled trial

1 reference

7 January 2021

Factors influencing the development of a hepatitis C exercise protocol: a literature review

1 reference

7 January 2021

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

1 reference

7 January 2021

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction

1 reference

7 January 2021

Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.

1 reference

7 January 2021

Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy

1 reference

7 January 2021

Paroxetine for the prevention of depression induced by high-dose interferon alfa

1 reference

7 January 2021

Interferon-induced depression: strategies in treatment.

1 reference

7 January 2021

Anemia in the Treatment of Hepatitis C Virus Infection

1 reference

7 January 2021

Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.

1 reference

7 January 2021

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.

1 reference

7 January 2021

Management of the hematologic complications of hepatitis C therapy

1 reference

7 January 2021

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

7 January 2021

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy

1 reference

7 January 2021

Prolonged course of pure red cell aplasia after erythropoietin therapy

1 reference

7 January 2021

Definition and management of anemia in patients infected with hepatitis C virus

1 reference

7 January 2021

Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21565

1 reference

16 August 2017

1 reference